Use of Adjuvant Sorafenib in Liver Transplant Recipients with High-Risk Hepatocellular Carcinoma

Table 1

Demographic characteristics.

	Sorafenib adjuvant therapy; 𝑛=7	Historical comparison group,; 𝑛=12
Average age ± SD (years)	56.1±10.5	56.7±6.0
Male (%)	6 (85.7)	10 (83.3)
HCV (%)	6 (85.7)	9 (75.0)
Mean HCC size ± SD (mm)	39.00 ± 21.21	37.50 ± 15.86
Mean AFP at OLT ± SD (ng/mL)	794±1229	880±1278
Mean lowest AFP after OLT ± SD (ng/mL)	3.96±5.30	65.35±204.02
Mean number of TACE* treatments on each patient	1.71	2.16

𝑃 values between groups not significant and not reported.
*Transarterial chemoembolization.